The Patenting of Human Genes and Biological Monopolies
Patent rules shape ownership claims over inventions related to biological information.
The Mechanism: Patent law in some jurisdictions has distinguished naturally occurring DNA from engineered applications such as complementary DNA, with rules varying by country and time. The US Supreme Court ruled in 2013 that naturally occurring DNA is not patentable merely because it was isolated.
The Philosophical Pivot: Biological information feels both discovered and interpreted. Ownership claims can reward invention while making inherited material seem like private property rather than part of a shared human condition.
The Horizon: Access to genetic testing and research depends on patents, regulation, clinical capacity, and public investment. A patent can influence competition, but it does not alone determine whether medicine is affordable or equitable.
The language of a biological monopoly raises questions about who benefits from translating shared biology into commercial tools. Patients, researchers, and communities need a voice in decisions about their data and access.
The future of medicine will depend on balancing incentives for discovery with the principle that people should not be excluded from understanding their own biology.
To discover something in the body is not automatically to own the body it came from.
What should remain accessible to everyone when a company turns biological knowledge into a product?